These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21741620)

  • 1. MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model.
    Matsuura S; Egi Y; Yuki S; Horikawa T; Satoh H; Akira T
    Brain Res; 2011 Sep; 1410():122-31. PubMed ID: 21741620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemia.
    Egi Y; Matsuura S; Maruyama T; Fujio M; Yuki S; Akira T
    Brain Res; 2011 May; 1389():169-76. PubMed ID: 21420942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke.
    Abdelkarim GE; Gertz K; Harms C; Katchanov J; Dirnagl U; Szabó C; Endres M
    Int J Mol Med; 2001 Mar; 7(3):255-60. PubMed ID: 11179503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation.
    Kaundal RK; Shah KK; Sharma SS
    Life Sci; 2006 Nov; 79(24):2293-302. PubMed ID: 16935310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of ONO-1924H, an inhibitor of poly ADP-ribose polymerase (PARP), on cytotoxicity of PC12 cells and ischemic cerebral damage.
    Kamanaka Y; Kondo K; Ikeda Y; Kamoshima W; Kitajima T; Suzuki Y; Nakamura Y; Umemura K
    Life Sci; 2004 Nov; 76(2):151-62. PubMed ID: 15519361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model.
    Ikeda Y; Hokamura K; Kawai T; Ishiyama J; Ishikawa K; Anraku T; Uno T; Umemura K
    Brain Res; 2005 Oct; 1060(1-2):73-80. PubMed ID: 16202986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effect of 4-amino-1,8-napthalimide, a poly(ADP ribose) polymerase inhibitor in middle cerebral artery occlusion-induced focal cerebral ischemia in rat.
    Kabra DG; Thiyagarajan M; Kaul CL; Sharma SS
    Brain Res Bull; 2004 Feb; 62(5):425-33. PubMed ID: 15168908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comet assay as a novel approach for studying DNA damage in focal cerebral ischemia: differential effects of NMDA receptor antagonists and poly(ADP-ribose) polymerase inhibitors.
    Giovannelli L; Cozzi A; Guarnieri I; Dolara P; Moroni F
    J Cereb Blood Flow Metab; 2002 Jun; 22(6):697-704. PubMed ID: 12045668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: a preclinical stroke trial.
    Culman J; Nguyen-Ngoc M; Glatz T; Gohlke P; Herdegen T; Zhao Y
    Exp Neurol; 2012 Dec; 238(2):243-53. PubMed ID: 22995601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia.
    Moroni F; Meli E; Peruginelli F; Chiarugi A; Cozzi A; Picca R; Romagnoli P; Pellicciari R; Pellegrini-Giampietro DE
    Cell Death Differ; 2001 Sep; 8(9):921-32. PubMed ID: 11526447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase.
    Moroni F; Cozzi A; Chiarugi A; Formentini L; Camaioni E; Pellegrini-Giampietro DE; Chen Y; Liang S; Zaleska MM; Gonzales C; Wood A; Pellicciari R
    Br J Pharmacol; 2012 Mar; 165(5):1487-500. PubMed ID: 21913897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
    Endres M; Wang ZQ; Namura S; Waeber C; Moskowitz MA
    J Cereb Blood Flow Metab; 1997 Nov; 17(11):1143-51. PubMed ID: 9390645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice.
    Teng F; Beray-Berthat V; Coqueran B; Lesbats C; Kuntz M; Palmier B; Garraud M; Bedfert C; Slane N; Bérézowski V; Szeremeta F; Hachani J; Scherman D; Plotkine M; Doan BT; Marchand-Leroux C; Margaill I
    Exp Neurol; 2013 Oct; 248():416-28. PubMed ID: 23876515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial-approached neuroprotection using pan-caspase inhibitor and poly (ADP-ribose) polymerase (PARP) inhibitor following experimental stroke in rats; is there additional benefit?
    Yap E; Tan WL; Ng I; Ng YK
    Brain Res; 2008 Feb; 1195():130-8. PubMed ID: 18207135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.
    Legos JJ; Lenhard SC; Haimbach RE; Schaeffer TR; Bentley RG; McVey MJ; Chandra S; Irving EA; Andrew A Parsons ; Barone FC
    Exp Neurol; 2008 Jul; 212(1):53-62. PubMed ID: 18462720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lutein enhances survival and reduces neuronal damage in a mouse model of ischemic stroke.
    Li SY; Yang D; Fu ZJ; Woo T; Wong D; Lo AC
    Neurobiol Dis; 2012 Jan; 45(1):624-32. PubMed ID: 22024715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates.
    Suzuki N; Suzuki M; Murakami K; Hamajo K; Tsukamoto T; Shimojo M
    Brain Res; 2012 Jan; 1430():93-100. PubMed ID: 22119394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective profile of novel SRC kinase inhibitors in rodent models of cerebral ischemia.
    Liang S; Pong K; Gonzales C; Chen Y; Ling HP; Mark RJ; Boschelli F; Boschelli DH; Ye F; Barrios Sosa AC; Mansour TS; Frost P; Wood A; Pangalos MN; Zaleska MM
    J Pharmacol Exp Ther; 2009 Dec; 331(3):827-35. PubMed ID: 19741150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke.
    Kim Y; Kim YS; Kim HY; Noh MY; Kim JY; Lee YJ; Kim J; Park J; Kim SH
    Mol Neurobiol; 2018 Sep; 55(9):7153-7163. PubMed ID: 29383691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
    Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.